← Back to Search

Baseline followed by 5-10% THC Validation for Cannabis

Phase 1
Waitlist Available
Led By Timothy L Brown, Ph.D.
Research Sponsored by ISBRG Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, 20, 30, 60, 90, 120 and 180 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial involves people who use cannabis and will test a new device to see if it can measure their impairment. The device uses special light and computer programs to detect THC levels in the blood.

Eligible Conditions
  • Cannabis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, 20, 30, 60, 90, 120 and 180 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 20, 30, 60, 90, 120 and 180 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Acute Subjective Response to Cannabis Score
Secondary study objectives
Blood Delta-9-THC
Standard Deviation of Lateral Position (SDLP) - Distracted
Standard Deviation of Lateral Position (SDLP) - Undistracted

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Baseline followed by 5-10% THC VerificationExperimental Treatment1 Intervention
Group II: Baseline followed by 5-10% THC ValidationExperimental Treatment1 Intervention

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ISBRG CorpLead Sponsor
1 Previous Clinical Trials
12,500 Total Patients Enrolled
National Advanced Driving SimulatorOTHER
Timothy L Brown, Ph.D.Principal InvestigatorNational Advanced Driving Simulator
1 Previous Clinical Trials
18 Total Patients Enrolled
~20 spots leftby Nov 2025